One other HER2-targeting drug, the small-molecule Tykerb (lapatinib from London-based GlaxoSmithKline), is now approved for use in breast cancer, but a bevy of next-generation versions of ...

Expert Rev Mol Diagn. 2008;8(4):417-434. The College of American Pathologists (CAP) and ASCO recently organized an expert panel, which conducted a systematic review of the literature and developed ...

目前，中国 NMPA 已受理了泽尼达妥单抗治疗HER2 +胆道癌二线治疗的上市申请，并将其纳入了优先审评。 胆道癌是一种起源于胆管上皮细胞的恶性肿瘤 ...

In addition to targeting a specific tumor protein, the treatment includes a bispecific antibody that enhances the therapeutic ...

significant ... increase in ... time to progression Lapatinib is an oral, reversible, small-molecule dual inhibitor of EGFR and HER2 tyrosine kinases that has demonstrated clinical activity in ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds coupled to an antibody via a linker molecule. The jury in the US District Court for ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...